NasdaqGM:TNGXBiotechs
Assessing Tango Therapeutics (TNGX) Valuation After Trial Progress And Leadership Changes
Tango Therapeutics (TNGX) is back in focus after reporting a first quarter net loss of US$45.51m, updating investors on clinical progress, and confirming multiple board resignations and leadership changes.
See our latest analysis for Tango Therapeutics.
Despite the sharp 17.33% one day and 18.83% one month share price declines following the wider first quarter loss and board exits, Tango Therapeutics still carries strong momentum, with a 130.24% year to date share price return and a very...